The market structure is expected to remain fragmented during the forecast period. Vendors are deploying different organic and inorganic growth strategies to compete in the market. Various players in the market are engaging in strategic partnerships and joint ventures coupled with launching differentiated products to up their game in the Sarcoma Therapeutics industry.
Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Bayer AG, Bristol Myers Squibb Co., CytRx Corp., Eisai Co. Ltd., Epizyme Inc., GlaxoSmithKline Plc, Johnson and Johnson Inc., Karyopharm Therapeutics Inc., Mirati Therapeutics Inc., Novartis AG, PharmaMar SA among others are some of the few key vendors competing to maintain their market position in the market.
View more about the market's vendor landscape highlights with a comprehensive list of vendors and their offerings.
Key Market Segmentation
- Segmentation by Type:
- Soft tissue sarcoma
- Soft tissue sarcoma therapies account for the majority of the global sarcoma therapeutics market. This is due to the recent introduction of innovative medicines in major markets. In 2020, Novartis' GLEEVEC accounted for around 25% of the market. These medications' strong efficacy and safety characteristics have resulted in growing demand. Clinical investigations have demonstrated that these medications have a high level of efficacy. As a result, the market is seeing an increase in the acceptance of these drugs, which is helping to drive market expansion.
- Osteosarcoma
Request a FREE Sample of this report for more highlights into the market segments.
Regional Market Outlook
North America will contribute to 37% of the market growth during the forecast period. The growth of this region can be attributed to the exponential growth of the sarcoma therapeutics industry owing to the rapidly progressive nature and the severity of the indication.
Apart from regions, if we look at the country-wise market growth, the US, Canada, China, Germany, and the UK will contribute to the highest market growth.
Download our FREE sample report for more key highlights on the regional market share of most of the above-mentioned countries.
Latest Trends, Driving the Global Home Textile Retail Market
- Market Driver:
- Patient assistance programs:
In recent years, the number of patient assistance programmers in the worldwide oncology medicines market has increased dramatically. This is attributed to rising therapy costs for various oncology reasons. Because pharmaceuticals account for a considerable portion of the cost structure, the high cost of therapeutics for cancer indications is a big concern for patients. To address this issue and minimize the financial burden on patients, governments and pharmaceutical companies are launching a number of patient assistance programmers.
Smaller particular markets present a difficulty for vendors, owing to limited distribution methods and a lack of knowledge of local markets in these regions. As a result, global players are forming strategic agreements with small and medium-sized pharmaceutical companies that dominate the market in these areas in order to expand medicine availability in local markets. Companies are also forming strategic collaborations to help with the development of novel therapeutics in the clinical stages, as well as the transfer of technology and the regional approval procedure. The high cost, on the other hand, is likely to hamper the market's expansion in the forecast term.
Find additional information about various other market drivers & trends mentioned in our FREE sample report.
Need More? Are You Looking for Information Not Covered in This Report?
- Want to understand more about the various research methodology?
- Evaluate a specific segment or region in detail
- Identify key suppliers, customers, or other market players
- Analyze market regulations
Tailor this report according to your needs. Get it done with our $1000 worth of free customization. Speak to Our Analyst Now!
Related Reports:
Acute Myeloid Leukemia (AML) Treatment Market in APAC by Type and Geography - Forecast and Analysis 2022-2026
Non-small Cell Lung Cancer Drugs Market by Product and Geography - Forecast and Analysis 2022-2026
Sarcoma Therapeutics Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9% |
Market growth 2022-2026 |
$ 1.18 billion |
Market structure |
Fragmented |
YoY growth (%) |
7.8 |
Regional analysis |
North America, Europe, APAC, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, China, Germany, and UK |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Bayer AG, Bristol Myers Squibb Co., CytRx Corp., Eisai Co. Ltd., Epizyme Inc., GlaxoSmithKline Plc, Johnson and Johnson Inc., Karyopharm Therapeutics Inc., Mirati Therapeutics Inc., Novartis AG, PharmaMar SA, SillaJen Co. Ltd., Athenex Inc., Eli Lilly and Co., and Pfizer Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Soft tissue sarcoma - Market size and forecast 2021-2026
- Exhibit 28: Chart on Soft tissue sarcoma - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Soft tissue sarcoma - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Soft tissue sarcoma - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Soft tissue sarcoma - Year-over-year growth 2021-2026 (%)
- 5.4 Osteosarcoma - Market size and forecast 2021-2026
- Exhibit 32: Chart on Osteosarcoma - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Osteosarcoma - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Osteosarcoma - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Osteosarcoma - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 North America - Market size and forecast 2021-2026
- Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.4 Europe - Market size and forecast 2021-2026
- Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.5 APAC - Market size and forecast 2021-2026
- Exhibit 50: Chart on APAC - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on APAC - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on APAC - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on APAC - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 China - Market size and forecast 2021-2026
- Exhibit 62: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.9 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.10 Canada - Market size and forecast 2021-2026
- Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)
- 7.11 UK - Market size and forecast 2021-2026
- Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 Agios Inc.
- Exhibit 85: Agios Inc. - Overview
- Exhibit 86: Agios Inc. - Business segments
- Exhibit 87: Agios Inc. - Key offerings
- Exhibit 88: Agios Inc. - Segment focus
- 10.4 Athenex Inc.
- Exhibit 89: Athenex Inc. - Overview
- Exhibit 90: Athenex Inc. - Product / Service
- Exhibit 91: Athenex Inc. - Key offerings
- 10.5 Bayer AG
- Exhibit 92: Bayer AG - Overview
- Exhibit 93: Bayer AG - Business segments
- Exhibit 94: Bayer AG - Key news
- Exhibit 95: Bayer AG - Key offerings
- Exhibit 96: Bayer AG - Segment focus
- 10.6 Eisai Co. Ltd.
- Exhibit 97: Eisai Co. Ltd. - Overview
- Exhibit 98: Eisai Co. Ltd. - Business segments
- Exhibit 99: Eisai Co. Ltd. - Key offerings
- Exhibit 100: Eisai Co. Ltd. - Segment focus
- 10.7 Epizyme Inc.
- Exhibit 101: Epizyme Inc. - Overview
- Exhibit 102: Epizyme Inc. - Business segments
- Exhibit 103: Epizyme Inc. - Key offerings
- Exhibit 104: Epizyme Inc. - Segment focus
- 10.8 GlaxoSmithKline Plc
- Exhibit 105: GlaxoSmithKline Plc - Overview
- Exhibit 106: GlaxoSmithKline Plc - Business segments
- Exhibit 107: GlaxoSmithKline Plc - Key news
- Exhibit 108: GlaxoSmithKline Plc - Key offerings
- Exhibit 109: GlaxoSmithKline Plc - Segment focus
- 10.9 Johnson and Johnson Inc.
- Exhibit 110: Johnson and Johnson Inc. - Overview
- Exhibit 111: Johnson and Johnson Inc. - Business segments
- Exhibit 112: Johnson and Johnson Inc. - Key news
- Exhibit 113: Johnson and Johnson Inc. - Key offerings
- Exhibit 114: Johnson and Johnson Inc. - Segment focus
- 10.10 Karyopharm Therapeutics Inc.
- Exhibit 115: Karyopharm Therapeutics Inc. - Overview
- Exhibit 116: Karyopharm Therapeutics Inc. - Key offerings
- 10.11 Novartis AG
- Exhibit 117: Novartis AG - Overview
- Exhibit 118: Novartis AG - Business segments
- Exhibit 119: Novartis AG - Key offerings
- Exhibit 120: Novartis AG - Segment focus
- 10.12 PharmaMar SA
- Exhibit 121: PharmaMar SA - Overview
- Exhibit 122: PharmaMar SA - Business segments
- Exhibit 123: PharmaMar SA - Key news
- Exhibit 124: PharmaMar SA - Key offerings
- Exhibit 125: PharmaMar SA - Segment focus
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 126: Inclusions checklist
- Exhibit 127: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 128: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 129: Research methodology
- Exhibit 130: Validation techniques employed for market sizing
- Exhibit 131: Information sources
- 11.5 List of abbreviations
- Exhibit 132: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article